Hôpital Fondation A. de Rothschild
Paris, 75019, France
Location status: Recruiting
NCT Number: NCT07316998
Myopia and high myopia are among the leading causes of visual impairment and blindness worldwide. The total number of people with myopia worldwide was estimated at 2.6 billion in 2020 and could reach 4.8 billion by 2050 unless preventive interventions are implemented.
Most epidemiological studies have focused on risk factors for myopia progression, with far fewer addressing the factors that cause a child to shift from emmetropia to myopia. The risk factors for the onset of myopia may be the same as those for myopia progression. However, for an equivalent level of risk exposure, it remains unclear why some children develop myopia while others do not.
Identifying the population most at risk of developing myopia would make it possible to propose preventive treatments aimed at delaying or preventing its onset. This would allow evaluation of the effectiveness of current myopia control treatments (peripheral defocus lenses, atropine, contact lenses) in preventing the onset of myopia, as well as future targeted treatments, including the potential benefit of early optical correction-a strategy once used but later abandoned due to a lack of robust scientific evidence.
The establishment of longitudinal follow-up of young emmetropic children at the French Institute of Myopia will enable the acquisition of high-quality imaging, allowing investigation of the association between advanced imaging parameters and external environmental factors with the onset of myopia.
Interested in participating?
Request Info4 year–8 year
All sexes
Observational
Paris, 75019, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
annual follow-up including ophtalmologic examination and biometry and behavioural questionnaires
Time frame: Annual follow up : Year 1 and year 2
Onset of myopia within the 2 years following inclusion, defined as a spherical equivalent (SE) ≤ -0.50 D in at least one eye. Measurement of the spherical equivalent will be performed under cycloplegia using an autorefractor.
Time frame: annual follow-up until Year 5
Onset of myopia within the 5 years following inclusion, defined as a spherical equivalent (SE) ≤ -0.50 D in at least one eye. Measurement of the spherical equivalent will be performed under cycloplegia using an autorefractor.
Contact information is provided by the study sponsor or research team.
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: PREMYOP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07567040
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial DetailsNCT07698977
Eye Diseases, Myopia
Budapest, Hungary
View Trial DetailsNCT07512102
Eye Diseases, Myopia
Guangzhou, Guangdong, China
View Trial DetailsNCT07512115
Eye Diseases, Myopia
Guangzhou, Guangdong, China
View Trial Details